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Bone grafts are a common procedure for treating craniofacial injuries such as 
trauma, surgery, and reconstruction.  Autografts and allografts have limitations which 
encourages the use of synthetic bone grafts.  While synthetic bone grafts, such as 
hydroxyapatite (HA) microspheres, are advantageous for their cost and reproducibility, 
they lack the cells and growth factors needed for proper osteoinduction.  Bone 
morphogenetic protein-2 (BMP-2) has been shown to increase the osteoinduction of grafts 
but the effective dose is above physiological levels and causes undesired effects on the 
body.  Relaxin has been shown to enhance BMP-2’s ability to induce bone formation in 
vitro and thus lower the dose of BMP-2 required for effective bone regeneration.  In this 
study, HA microspheres sized 212-250µm were synthesized; the in vitro release of BMP-
2 and relaxin into a medium of fetal bovine was measured.  The release of both was slow 
and controlled and no hindrance to release was seen when both proteins were loaded on 
the microspheres.  When implanted into rat calvarial defects for 6 weeks, an enhancement 
to new bone percent was seen when loading HA microspheres with 0.5µg BMP-2 and 
0.05µg of relaxin compared to microspheres loaded with 0.5µg BMP-2 alone.  A 50% 
reduction in BMP-2 dose, compared to a previously published dose, was seen when relaxin 
(at 0.05, 0.1, and 0.25µg per defect) was loaded on the HA microspheres.  A 75% reduction 
in BMP-2 dose was seen when 0.05µg per defect of relaxin was loaded.  These results 
suggest that a combination of relaxin and BMP-2 loaded onto HA microspheres will reduce 
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Approximately 3 million bone grafts are performed annually in the United States 
for treatment of large bone defects [1].  Bone defects can result from trauma, malignancy 
or congenital diseases and are a significant clinical problem.  Trauma in the craniofacial 
region poses a great challenge to bone growth due to the location of highly important 
anatomic structures [2].  Bone has a high capability to regeneration on its own with a three 
stage bone repair process.  These three stages are the early inflammatory stage, the repair 
stage and the late remodeling stage [3].  During the inflammatory stage a hematoma 
develops allowing inflammatory cells and fibroblasts to enter and form granulation tissue 
[3].  In the repair stage, fibroblasts form a stroma to support vascular growth [3].  A 
collagen matrix is laid down and mineralized leading to the formation of a soft callus [3].  
The callus eventually ossifies and forms a bridge of bone over the fracture [3].  The 
remodeling stage is the longest and results in the bone being restored to its original shape 
and mechanical strength [3].   
When it is impractical to allow bone to naturally heal on its own bone grafts can be 
used to treat bone defects.  Bone grafts can have osteoconductive or osteoinductive 
properties.  Osteoconduction is the process in which the graft allows osteogenic cells to 
have a biological role, while osteoinduction involves the molecules, such as growth factors, 
that influence the fate of osteogenic cells [4].  Autografts are considered the gold standard 
for treatment because they have osteoinductive effects and do not cause an adverse immune 
response in the patient.  However, donor site limitations and morbidity remain obstacles 
for using them [5]. Allografts lack the risk of host site morbidity, but are costly and risk a 




to circumvent limitations of both autografts and allografts.  These include bioceramics 
(hydroxyapatite (HA), beta-tricalcium phosphate (β-TCP), and biphasic calcium phosphate 
(BCP)), bioactive glass, and polymers (e.g. hyaluronic acid) [1] .  β-TCP is known for its 
high strength similar to cancellous bone but has a low replacement ratio (more β-TCP is 
resorbed than replaced with new bone) which has limited its clinical use [6].  BCP are 
mixtures of β-TCP and HA and release calcium and phosphate ions into the defect as the 
scaffold is resorbed [6].  Bioactive glass, such as 45S5 glass, reacts in the body to form a 
layer of hydroxyapatite and supports the regeneration of bone [1].  Polymers like 
hyaluronic acid have the ability to combine with other materials to enhance the properties 
but natural polymers have a risk for an immune response [7].  Hyaluronic acid has also 
been used as a delivery method for the release of growth factors [7].  Synthetic  bone grafts 
can be made in large quantities, have reproducible quality, and typically do not have an 
adverse host response [8].  Unfortunately, synthetic bone grafts are limited by their 
osteoconductive rather than osteoinductive capabilities because they lack the 
osteoprogenitor cells [8, 9].  Since they do not produce significant bone regeneration 
compared to autografts, the addition of growth factors is needed.   
Hydroxyapatite (HA) is an ideal biomaterial for synthetic bone grafts because it 
consists of the inorganic elements found in natural bone [6].  Its chemical formula is 
Ca10(PO4)6(OH)2 and therefore it consists of calcium and phosphate ions.  This makes HA 
highly biocompatible since it produces no toxicity or immune response. [9].  HA has also 
been known to promote cell adhesion and growth when produced with adequate pore sizes, 
typically 100µm [6, 10].  Another quality of HA is its ability to adsorb different types of 




mechanical strength, limiting its use in load bearing bones, and its low degradation rate [6, 
12].  Microspheres composed of HA have a high affinity to growth factors and can be used 
as a delivery vehicle [13].  Delivery systems are typically composed of porous particles, 
granules, or scaffolds in which the bioactive protein is either adsorbed to the surfaces of 
the porous material, or encapsulated within the pores [14].  Hollow HA microspheres have 
a large surface area due to their mesoporous shell [14].  This allows for an enhanced 
capability to release growth factors because absorption can occur in the shell and within 
the hollow core [13]. This mesoporous structure can also enhance cell adhesion [15].  The 
absorption and release of growth factors from HA microspheres make them a model carrier.   
Bone morphogenetic protein 2 (BMP-2), a member of the TGF-β superfamily, is a 
strong inducer of osteogenesis [16].  BMP-2 is naturally found at a concentration of 2ng/g 
of bone and in serum at a concentration of about 90pg/mL [17, 18].  BMP-2 is one of two 
BMP proteins currently used in clinical settings for orthopedic and dental applications [18].  
Adversely, BMP-2 has a tendency to rapidly degrade (half-life of about 7 to 16 minutes) 
when injected directly into a defect site, due to proteases.  Therefore, a supraphysiological 
dose of the protein is typically required.  This supraphysiological dose can cause some 
undesired side effects like swelling and an increased risk for cancer (more than three times 
the incident rate) [7, 19, 20].  Because of this, it is preferable to have controlled release of 
BMP-2 in a localized environment since it will lower the required dose and reduce side-
effects.  At similar doses it has been shown that controlled, long-term delivery of BMP-2 
is more effective and safer compared to short-term delivery [21].  Currently, the only 
carriers clinically approved for drug delivery are collagen scaffolds [18].  Unfortunately, 




release [22].  HA microspheres have been shown as a novel system for controlled drug 
release due to a decreased initial burst and sustained release of BMP-2 [23, 24].   
In additional to providing the controlled release of BMP-2 to reduce undesired 
effects, an enhancer to BMP-2 can be used to potentially decrease the required dose of 
BMP-2.  Relaxin is an example of such an enhancer.  Relaxin is a pleiotrophic hormone of 
the insulin family [25].  It is typically known as a pregnancy hormone, in which it has a 
role in promoting cervical softening to facilitate birth [25].  Relaxin also has roles in 
connective tissue metabolism, collagen turnover, angiogenesis, and tumor metastasis [26, 
27].  Relaxin 2, which is the only relaxin protein found circulating in the blood, acts equally 
through the Relaxin/insulin-like family peptide receptors (Rxfp) 1 and 2, although the 
Rxfp2 receptor is known to play a larger role in osteogensis [25, 28].  These receptors have 
been recently found on bone tissue, namely osteoblasts, notably on mouse calvarial tissue 
[29, 30].  While examining the effects of relaxin on mesenchymal stem cell differentiation 
into osteoblasts and bone formation, Moon et al found that relaxin augmented BMP-2-
induced osteogenesis [26].  When determining the effects that relaxin played on 
C3H/10T1/2 mouse embryonic fibroblast cells it was found that relaxin was not an inducer 
of osteogenesis but an enhancer to BMP-2.  It is believed that a combination of BMP-2 and 
relaxin may provide satisfactory bone regeneration therefore leading to a reduction of the 
necessary BMP-2 dose.   
Previous studies have investigated bone regeneration using HA microspheres and 
the growth factors transforming growth factor beta (TGF-β) and BMP-2.  Loading the 
microspheres with 1µg per defect of BMP-2 provided considerable bone regeneration at 




and required a higher dosage (5µg per defect) [13].  In a quick comparison, this dose of 
BMP-2 is lower than the dosage used by other types of calcium phosphates and other 
biomaterials [8].  However, continuing to lower this dose will contribute to a reduction in 
clinically-relevant, unwanted side effects.   
The present study hypothesizes that the use of relaxin will lower the dose of BMP-
2 required to achieve sufficient bone regeneration.  Bone regeneration in rat calvarial 
defects was analyzed using histomorphometric analysis.  The rat calvarial defect was used 








2. MATERIALS AND METHODS 
2.1. PREPARATION AND CHARACTERIZATION OF HA MICROSPHERES 
Closed HA microspheres were prepared by reacting glass microspheres in a 
phosphate buffer as described in a previous publication [23].  Briefly, borate glass with a 
composition of 15CaO, 11Li2O and 74B2O3 was prepared by melting reagent grade CaCO3, 
Li2CO3, and H3BO3 in a Pt crucible at 1200°C for 45 minutes and quenching the melt 
between cold stainless steel plates.  Particles of size 212-250 µm were obtained by grinding 
the glass in a hardened steel mortar and pestle, and sieving through 212 and 250 mesh 
sieves.  The glass particles were dropped down a vertical tube furnace at 1000°C to obtain 
glass microspheres.  The glass microspheres were reacted for two days in 0.02M K2PO4 
solution at 37°C at a starting pH of 9.0 to produce hollow HA microspheres.  The convert 
microspheres were washed three times with distilled water, soaked in ethanol to remove 
residual water and dried for twelve hours at room temperature ad for twelve hours at 90°C.    
Characterization of the converted microspheres was performed using scanning 
electron microscopy (SEM).  Briefly, the microstructure of the surface and cross-section 
of the microspheres was examined using scanning electron microscopy (SEM; S4700; 
Hitachi, Tokyp, Japan).  The specific surface area of the microspheres and pore size was 
measured using nitrogen adsorption (Autosorb-1; Quantachrome, Boynton Beach, FL) as 
previously described [8].  The carbon content was measured, previously, using a 
combustion technique at a commercial laboratory (LECO Corp., St Joseph, MI).  X-ray 
diffraction (XRD) and Fourier transform infrared (FTIR) spectroscopy was used to check 




(λ=0.15406 nm) at a rate of 1.8°/min in the 2θ range 20-70°, while FTIR was performed in 
the range of 400-4000 cm-1.   
 
2.2. RELEASE PROFILE OF BMP-2 
Human recombinant BMP-2 was purchased from Shenandoah Inc. (Warwick, PA) 
and diluted in sterile water to a concentration of 10µg/mL.  10mg of HA microspheres were 
placed in the BMP-2 solution.  A small vacuum was used to remove any air trapped in the 
microspheres then allowed to dry in 4°C overnight.  The microspheres were placed in a 
buffer consisting of fetal bovine serum (FBS) and phosphate buffered saline (PBS) at a 1 
to 1 ratio and kept at 37°C with gentle agitation.  After 1 hour, 1 day, 3 days, 5 days, 7 
days, and 14 days, the entire release buffer was collected.  The microspheres were then 
rinsed with additional release buffer and the rinse was collected and pooled with the 
previous collection, making sure not to collect any microspheres in the process.  Fresh 
buffer was then added to continue the experiment.  The amount of BMP-2 released was 
measured using an enzyme-linked immunosorbent assay (ELISA) kit (Peprotech, Rocky 
Hill, NJ).   Absorbance was measured with a microplate reader (BMG LABTECH, 
FLUOstar Omega).  The concentration of the unknown samples was compared to a 
standard curve ran at the same time.   
 
2.3. RELEASE PROFILE OF RELAXIN  
The release profile of relaxin was conducted like the release profile for BMP-2 
mentioned above.  Human recombinant Relaxin-2 was purchased from R&D systems 




microspheres were placed in the relaxin solution.  The remaining procedure was followed 
exactly as mentioned above.  Samples were collected after 1 hour, 1 day, 2 days, 3 days, 5 
days, 7 days, and 14 days.  The amount of relaxin released was measured using an ELISA 
kit (R&D systems).   The concentration of the unknown samples was compared to a 
standard curve ran at the same time.   
 
2.4. RELEASE PROFILE OF A COMBINATION OF BMP-2 AND RELAXIN 
The combined release was conducted in a similar manner to the individual release 
profiles mentioned above.  Briefly, 10mg of HA microspheres were placed in a solution 
containing both 10µg/mL of BMP-2 and 1µg/mL of relaxin.  The remaining procedure will 
be followed exactly like the individual release profiles mentioned above.  Samples were 
collected after 1 hour, 1 day, 2 days, 3 days, 5 days, 7 days, and 14 days.  The amount 
released of either protein was measured using their respective ELISA.   
 
2.5. ANIMALS 
All animal procedures were approved by the Missouri University of Science and 
Technology Institutional Animal Care and Use Committee (IACUC), in compliance with 
the NIH Guide for Care and Use of Laboratory Animals [31].  Sixty male Sprague Dawley 
rats of three months old were purchased from Envigo (Indianapolis, IN) (weighing between 
350 and 400g) and housed under a 12h/12h light/dark cycle.  They were allowed to 
acclimate to diet, water and housing for 14 days before the experiment was conducted.  All 





The rats were anesthetized with 3-5% isoflurane in oxygen administered by 
inhalation or an intraperitoneal injection of ketamine (70 mg/kg), xylazine (7 mg/kg).  The 
surgical area was shaved, scrubbed with 70% ethanol, and draped with a sterile drape.  
Using aseptic technique, a cranial skin incision was made in an anterior-to-posterior 
direction.  The subcutaneous tissue, musculature, and periosteum were dissected to expose 
the calvarium.  Bilateral full-thickness defects 4mm in diameter were created using a 
trephine burr and an electric drill.  The site was constantly irrigated with sterile PBS to 
prevent overheating.  The defects were implanted with 13 groups of implants consisting of 
closed hollow HA microspheres (10 mg per defect) loaded with varying amounts of 
Relaxin and BMP-2 and are detailed in Table 2.1.  
Care was taken to avoid mixing implants containing different proteins in the same 
animal.  The animals were monitored daily and after 6 weeks the animals were sacrificed 
by CO2 inhalation.  The calvarial defect sites and surrounding bone were harvested.   
 
2.7. HISTOLOGY 
The calvarial samples were washed and fixed in a 10% formalin solution for 5 days. 
The fixed samples were cut transversely in half; half of each sample was for paraffin 
embedding and the other half was for methyl methacrylate embedding.   
The paraffin embedded samples were decalcified for 10 days in 14% EDTA and 
later dehydrated in ethanol and embedded in paraffin using standard histological 
techniques.  Sections of 5µm were made from the samples and stained with hematoxylin 




Table 2.1.  Detailed description of the amount of BMP-2 and relaxin loaded in the 13 
groups used in the study. 
Group BMP-2 (µg) Relaxin (µg) Description 
1 0 0 As prepared microspheres 
2 0 0.05 Relaxin alone 
3 0 0.1 Relaxin alone 
4 0 0.25 Relaxin alone 
5 0.25 0 BMP-2 alone 
6 0.5 0 BMP-2 alone 
7 1 0 BMP-2 alone 
8 0.25 0.05 0.25µg BMP-2 + Relaxin 
9 0.25 0.1 0.25µg BMP-2 + Relaxin 
10 0.25 0.25 0.25µg BMP-2 + Relaxin 
11 0.5 0.05 0.5µg BMP-2 + Relaxin 
12 0.5 0.1 0.5µg BMP-2 + Relaxin 




The methyl methacrylate embedded samples were dehydrated in ethanol and 
embedded in Poly(methyl methacrylate) (PMMA).  The sections were affixed to acrylic 
slides, ground down to 40μm using a surface grinder (EXAKT 400CS, Norderstedt, 
Germany) and stained using the von Kossa method to observe mineralization [33].  
 
2.8. HISTOMORPHOMETRIC ANALYSIS 
Transmitted light images of the stained sections were taken with an Olympus BX 
53 microscope connected to a CCD camera (DP70, Olympus, Japan) and were analyzed 




was determined from the H&E stained samples.  The total defect area was identified by 
measuring one edge of the old calvarial bone to the other edge including the implants and 
tissue within.  The new bone within the defect area was outlined and expressed as a 
percentage of the total defect area.   
 
2.9. STATISTICAL ANALYSIS 
Data sets are presented as means ± standard deviation. Data were compiled in 
Microsoft Excel and statistical analysis was performed using Minitab 17. A student’s t-test 
was conducted to determine statistical significance between two samples.  One-way 
analysis of variance (ANOVA) with Dunnett’s method pairwise comparison plots was used 
to determine and identify statistically significant values. Values were considered 






3.1. CHARACTERIZATION OF HA MICROSPHERES 
Scanning electron microscope (SEM) images of the hollow HA microspheres are 
shown in Figure 3.1A and B.  The hollow HA microspheres had a diameter of 212-250µm, 
with a surface area of 168.0 m2/g and a mesoporous shell wall with a pore size of 10.12 
nm.  The total pore volume of the HA microspheres was determined, by nitrogen 










The x-ray and Fourier transform infrared spectroscopy (FTIR) patterns of the 
hollow HA microspheres were described in previous publications[8, 23].   The X-ray 
powder diffraction (XRD) patterns confirmed that the hollow HA microspheres were 
composed of nanometer-sized HA crystals, while the resonances in the FTIR spectrum 
were associated with crystalline HA.  The FTIR results also showed a weak resonance 
corresponding to the CO3




process.  The carbonate content was determined to be 2.1% based on the combustion 
analysis.   
 
3.2. RELEASE PROFILE 
The amount of BMP-2 released from hollow HA microspheres, at particular time 
points, into the FBS:PBS release buffer is shown in Figure 3.2A.  The medium was 
completely removed at each time point and fresh medium was added.  The release at select 
time points was used to determine the cumulative release of BMP-2 (Figure 3.2B).   
 HA microspheres loaded with BMP-2 alone showed an initial burst release at 1 
hour then continued release at the following time points.  Microspheres loaded with a 
combination of BMP-2 and relaxin did not show a burst release and instead had a more 
continuous but lower release throughout the course of the experiment.  Regardless of the 
high initial burst or continuous release over the time points, both groups, BMP-2 alone and 
BMP-2 combined with relaxin group, had comparable final release amounts at the 
termination of the experiment (p=0.287; n=3).  The final released amount of the alone 
group was 13.1ng when compared to the initial load amount. Similarly, the final released 
amount of the combination group was 10.3ng when compared to the initial load amount. 
 The amount of relaxin released from hollow HA microspheres, at particular time 
points, into the release buffer is shown in Figure 3.2C.  As previously described, the 
medium was completely removed at each time point and fresh medium was added.  The 
release of relaxin at select time points was used to determine the cumulative release (Figure 




When loaded with relaxin alone and relaxin simultaneously loaded with BMP-2, 
microspheres showed an initial burst release of relaxin similar to microspheres loaded with 
BMP-2 alone.  Continued release was noted in both samples; however, the relaxin alone 
group had a greatly decreased release after 1 day.  Microspheres loaded in combination 
with BMP-2 showed significantly higher cumulative release compared to microspheres 
loaded alone (p=0.001; n=3).  The final released amount of relaxin alone was 150pg when 
compared to the initial loaded amount. For relaxin with BMP-2, the final released amount 





Figure 3.2. Release profiles of A-B) BMP-2 and C-D) Relaxin from hollow HA 
microspheres. A) amount of BMP-2 release when loaded alone or in combination with 
relaxin at selected time points, B) cumulative amount of BMP-2 released as a function of 
time C) amount of relaxin released when loaded alone or in combination with BMP-2 at 
selected time points, D) cumulative amount of relaxin released as a function of time.  






3.3. H&E STAINING 
H&E stained sections of rat calvarial defects implanted with as prepared HA 
microspheres and microspheres loaded with different amounts of BMP-2 are shown in 
Figure 3.3.  The as prepared microspheres showed little new bone growth (4±6%) which 
occurred along the edges to the host bone (Figure 3.3A).  The defect area instead consisted 
of fibrous connective tissue.  The addition of 0.25µg of BMP-2 per defect did not 
significantly increase new bone growth (p=0.129; n=6) (Figure 3.3B).  The addition of 
BMP-2 only significantly increased the new bone growth seen in the defect at amounts 
greater than 0.5µg per defect (24±12%; p=0.006; n=6) (Figure 3.3C).  The greatest new 
bone growth was seen when using microspheres loaded with 1µg per defect (40±6%) 
(Figure 3.3D).  New bone bridged the defect in samples loaded with 1µg BMP-2 within 
the 6-week period.   
H&E stained sections of rat calvarial defects implanted with HA microspheres 
loaded with different amounts of relaxin are shown in Figure 3.4.  Little new bone growth 
was seen in defects loaded with 0.05µg, 0.1µg, and 0.25µg of relaxin and was not 
significantly different than as prepared HA microspheres with p-values of 0.177, 0.541, 
and 0.401 (n=7), respectively (Figure 3.4B, C, and D).  Bone growth was only seen adjacent 
to host bone and from the dura mater, which is a source of osteogenic cells and growth 
factors.  
Images of H&E stained sections loaded with 0.25µg of BMP-2 and varying 
amounts of relaxin are shown in Figure 3.5.  Defects loaded with all tested concentrations 





Figure 3.3. H&E stained sections of rat calvarial defects implanted for 6 weeks with A) 
as prepared HA microspheres, B) HA microspheres loaded with 0.25µg of BMP-2, C) 
loaded with 0.5µg of BMP-2, D) loaded with 1µg of BMP-2.  HB= host bone; NB= new 




significant improvement in new bone growth compared to defects loaded with 0.25µg 
BMP-2 alone (p=0.105, 0.856, and 0.800, respectively, n=7).  New bone growth bridged 
the gap of the defect in samples of microspheres loaded with 0.25µg BMP-2 and 0.05µg 
relaxin (Figure 3.5B). 
 Figure 3.6 shows H&E stained sections of rat calvarial defects implanted with HA 








of relaxin (0.05µg, 0.1µg, and 0.25µg) showed significant new bone growth as new bone 





Figure 3.4.  H&E stained sections of rat calvarial defects implanted for 6 weeks with A) 
as prepared HA microspheres, B) HA microspheres loaded with 0.05µg of relaxin, C) 




loaded with 0.5µg of BMP-2 and 0.05µg of relaxin showed significant enhancement of 
bone growth compared to 0.5µg BMP-2 alone (p=0.002; n=7) (Figure 3.6B).  
High magnification images of select groups are shown in Figure 3.7.  The image of 




Figure 3.5.  H&E stained sections of rat calvarial defects implanted for 6 weeks with HA 
microspheres loaded with A) 0.25µg of BMP-2, B) 0.25µg of BMP-2 + 0.05µg of 
relaxin, C) 0.25µg of BMP-2 + 0.1µg of relaxin, D) 0.25µg of BMP-2 + 0.25µg of 




consisted of mostly fibrous connective tissue (Figure 3.7A).  More new bone area is seen 
in defects loaded with 0.5µg BMP-2 along with 0.05µg relaxin when compared to those 
loaded with 0.5µg BMP-2 alone.  This confirmed an enhancement effect of relaxin on 
BMP-2 at this amount (Figure 3.7C and D).  High magnification images of defects loaded 
with 1µg of BMP-2 looked histologically comparable to defects loaded with a combination 





Figure 3.8 shows the dose response in new bone growth with varying amounts of 
BMP-2 or relaxin.  Bar graphs depicting the enhancement effects of relaxin on 0.25µg 
BMP-2 and 0.5µg BMP-2 are shown in Figure 3.9.  The mean ± SD of the new bone 





Figure 3.6.  H&E stained sections of rat calvarial defects implanted for 6 weeks with HA 
microspheres loaded with A) 0.5µg of BMP-2, B) 0.5µg of BMP-2 and 0.05µg of relaxin, 
C) 0.5µg of BMP-2 and 0.1µg of relaxin, D) 0.5µg of BMP-2 and 0.25µg of relaxin.  




3.4. COMPARISON TO 1µg OF BMP-2 
Comparisons of BMP-2 and relaxin groups to a previously published effective 
dose of 1µg per defect are shown in Figure 3.10.  No significant difference in new bone 
percent was seen when 0.5µg of BMP-2 were loaded in HA microspheres with 0.05µg, 
0.1µg, and 0.25µg of relaxin when compared to those loaded with 1µg of BMP-2.  The p-





Figure 3.7. High magnification images of H&E stained sections of rat calvarial defects 
implanted for 6 weeks with A) as prepared HA microspheres, B) HA microspheres 
loaded with 0.5µg of BMP-2, C) HA microspheres loaded with 1µg of BMP-2, D) HA 
microspheres loaded with 0.5µg of BMP-2 and 0.05µg of relaxin.  HB= host bone, NB= 
new bone, HA= hydroxyapatite, BM= bone marrow-like tissue, CT= fibrous connective 




in new bone percent was observed between HA microspheres loaded 0.25µg of BMP-2 and 
0.05µg of relaxin when compared to microspheres loaded with 1µg of BMP-2 (p=0.357; 





Figure 3.8. The percent new bone formed in rat calvarial defects implanted for 6 weeks 
with HA microspheres loaded with A) doses of BMP-2, B) doses of relaxin.  Graph is 





Figure 3.9.  The enhancement effect of relaxin on rat calvarial defects implanted with A) 
HA microspheres loaded with 0.25µg of BMP-2 B) HA microspheres loaded with 0.5µg 




and can still provide effective bone regeneration.   
New bone percent for microspheres loaded with 0.25µg and 0.5µg of BMP-2 were 




respectively).  New bone percent for microspheres loaded with 0.05µg, 0.1µg, 0.25µg of 
relaxin was significantly lower when compared to microspheres loaded with 1µg of BMP-
2 with all p-values<0.001.  New bone percent for microspheres loaded with 0.25µg of 
BMP-2 along with 0.1µg and 0.25µg of relaxin was significantly lower compared to 
microspheres loaded with 1µg of BMP-2 (p=0.006 and 0.008, respectively).   
This demonstrates that use of either a lower dose of BMP-2 or relaxin alone will 
not have a comparable effect for bone regeneration compared to the published dose.  A 
combination of 0.25µg of BMP-2 and either 0.1µg or 0.25µg of relaxin cannot produced 




Table 3.1.  Percentage new bone (mean ± SD) in rat calvarial defects with varying 

























4±6 16±5 13±7 14±6 
0.25 18±8 29±13 21±9 21±7 
0.5 24±12 50±15 33±16 36±6 






3.5. VON KOSSA STAINING 
Figure 3.11 shows von Kossa stained sections of rat calvarial defects implanted for 
6 weeks with as prepared HA microspheres and microspheres loaded with different 
amounts of BMP-2.  Von Kossa stains phosphate ions, a dark brown-black, which can be 
found, within the defect, along the surface of the microspheres as well as in the new bone 
area.  Von Kossa is used as a verification of new bone area within the defect.  An increase 
in the amount of stained area correlates to the increase in amount of BMP-2.  The von 
Kossa stained area corresponds, histologically, to the new bone growth seen in the H&E 
stained images of Figure 3.3.   
Figure 3.12 shows von Kossa stained sections of rat calvarial defects implants for 





Figure 3.10. Comparison of the percent new bone formed in rat calvarial defects 
implanted with BMP-2 and relaxin to a previously published dose of 1µg per defect (1B).  





amounts of relaxin.  Minimal new bone growth is seen in these samples and corresponds 
to the H&E images in Figure 3.4 and the new bone percent shown in Table 3.1.  
Von Kossa stained sections of defects implanted using HA microspheres loaded 
with 0.25µg of BMP-2 and various amounts of relaxin are seen in Figure 3.13.  Defects 
loaded with 0.25µg of BMP-2 and either 0.25µg or 0.1µg of relaxin did not show a 
difference in von Kossa stained area compared to defects loaded with 0.25µg of BMP-2 





Figure 3.11.  Von Kossa stained sections of rat calvarial defects implanted for 6 weeks 
with A) as prepared HA microspheres, B) HA microspheres loaded with 0.25µg of BMP-




relaxin showed an increase in von Kossa stained area with brown shades seen between 
microspheres (Figure 3.13B).   
 Von Kossa stained sections of defects implanted with HA microspheres loaded with 





Figure 3.12. Von Kossa stained sections of rat calvarial defects implanted for 6 weeks 
with A) as prepared HA microspheres, B) HA microspheres loaded with 0.05µg of 





0.5µg of BMP-2 along with either 0.25µg or 0.1µg of relaxin, von Kossa stained area did 




loaded with a combination of 0.5µg of BMP-2 and 0.05µg of relaxin showed von Kossa 
staining in more than 90% of the in between microsphere area (Figure 3.14B).  This 




Figure 3.13.  Von Kossa stained sections of rat calvarial defects implanted for 6 weeks 
with HA microspheres loaded with A) 0.25µg of BMP-2, B) 0.25µg of BMP-2 + 0.05µg 
of relaxin, C) 0.25µg of BMP-2 + 0.1µg of relaxin, D) 0.25µg of BMP-2 + 0.25µg of 





Figure 3.14. Von Kossa stained sections of rat calvarial defects implanted for 6 weeks 
with HA microspheres loaded with A) 0.5µg of BMP-2, B) 0.5µg of BMP-2 + 0.05µg of 
relaxin, C) 0.5µg of BMP-2 + 0.1µg of relaxin, D) 0.5µg of BMP-2 + 0.25µg of relaxin.  






HA microspheres have been shown to be a carrier for growth factors while being 
osteoconductive and bioactive [8].  The present study aimed to test the ability of relaxin to 
enhance the osteoinductive effect of BMP-2 and to lower the required dose of BMP-2 for 
safer clinical use.  HA microspheres were tested for their control of the release of both 
BMP-2 and relaxin alone as well as in combination.  In vivo studies were conducted to test 
the enhancement effect of relaxin and showed enhancement and an ability to lower the 
BMP-2 dose at certain amounts.  
The results of BMP-2 release from the hollow HA microspheres were continuous 
and controlled but little was released over the measure time period (Figure 3.2B).  BMP-2 
and other similar growth factors have a high affinity to bind to hydroxyapatite [34].  This 
high affinity can result in an increase in adsorption but little release from the carrier.  BMP-
2 is believed to absorb on to HA with binding between functional groups on the BMP-2 
protein and the calcium site of HA [35].  This can explain the low release percent of the 
initial amount (13%), assuming total absorption.  The release profile in this study was 
carried out in a FBS:PBS system.  A higher release rate has been observed in vivo when 
compared to in vitro because of a higher degradation rate of HA and the higher solubility 
of proteins in vivo [8].  The current gradual release profile informs us that the HA 
microspheres developed in this study can be used as a controlled release system.  The 
dilemma between high affinity ad low release can be resolved by modifications of the 
microspheres.   
Aggregation of the microspheres as well as the lack of media flow have influenced 




microspheres degrade, however degradation of hydroxyapatite can take up to two years.  
Rohanizadeh and Chung tested different methods for incorporation of BMP-2 to HA and 
found the immersion technique used in this study had the lowest release percentage [35].  
Use of either of the other two methods, incorporation during HA precipitation or 
incorporation during dicalcium phosphate dehydrate conversation, may lead to higher 
release.  Testing in vivo release may more accurately depict responses for the bone 
regeneration of rat calvarial defects tested.   
The results of relaxin release from HA microspheres were continuous but ended 
with a much lower release rate than BMP-2 release (Figure 3.2D).  A lower affinity of 
relaxin to HA could be the reason for this lower release because the protein may not have 
adsorbed into the hollow HA core.  The isoelectric point of proteins has an effect on 
adsorption on to hydroxyapatite [36, 37].  With an isoelectric point of 8.5, BMP-2 has a 
positive charge when in the neutral release buffer, consisting of PBS and FBS, and is 
attracted to hydroxyapatite, which has a negative charge.  Relaxin, however, has an 
isoelectric point of 6.7 and therefore has a slight negative charge in the release buffer.  Zhao 
et al measured the release of hemoglobin, another neutral protein, from hydroxyapatite 
[38].  They found that at a neutral pH of 7.2, release of hemoglobin was the lowest 
compared to a more acidic pH [38].  Testing the solution after loading may further 
determine whether the low release percent is due to low adsorption of relaxin or low release 
of the incorporated amount.  The release rate of relaxin from HA microspheres can be 
improved before use in vivo.  While the rate was continuous with a slight initial burst 




rate in vivo is much higher than release rate in vitro, we anticipate that the effect would be 
more substantial.    
The release of BMP-2 and relaxin when loaded simultaneously onto HA 
microspheres can be seen in Figure 3.2.  This was to verify that loading multiple proteins 
onto HA microspheres would not negatively impact the release of the individual proteins.  
In the case of BMP-2, addition of relaxin didn’t not significantly lower the amount 
released.  The addition also resulted in no initial burst release of BMP-2 into the release 
buffer.  The co-release of BMP-2 and relaxin must lead to a more controlled release of 
BMP-2.  This shows that loading additional proteins will not affect BMP-2 release and can 
be used in situations that require the release of multiple growth factors for sufficient tissue 
regeneration.  For relaxin, the addition of BMP-2 significantly increased the amount of 
relaxin released.  This shows that BMP-2 must have changed the ability of relaxin to bind 
to HA and increased the amount bound and subsequently released.   
Figure 3.3 shows the dose response effect of BMP-2.  As BMP-2 is a osteoinductive 
protein, an increase in the amount of BMP-2 can increase new bone formation.  1µg per 
defect produced the most new bone, with a significant increase from as prepared 
microspheres seen at 0.5µg per defect.  This is demonstrated in Figure 3.8A.  Figure 3.4 
shows the dose response of relaxin.  Relaxin is known as an enhancer to BMP-2 and does 
not have any osteoinductive properties on its own [26].  In the present study, relaxin did 
not produce any significant bone regeneration compared to as prepared microspheres 
(Figure 3.8B).   
Figures 3.5 and 3.6 show the enhancement effect of relaxin to 0.25µg and 0.5µg of 




2, no enhancement effect was seen at any measured amount of relaxin.  At an amount of 
0.05µg an enhancement effect can be seen on 0.5µg of BMP-2.  Interestingly, at 0.5µg of 
BMP-2 no enhancement effect was seen at any other amounts of relaxin.  Too much relaxin 
may have an inhibitory effect by over activation of similar growth factor pathways.  
Relaxin works through the TGF-β pathway which is closely related to the BMP pathway 
[25].  Activation of both these bone regeneration pathways may lead to a reduction of the 
enhancement effect.  Additional studies can use even further reduced amounts of relaxin 
to determine the range for a significant enhancement effect.  No enhancement effect can 
be seen with any amount of relaxin at 0.25µg of BMP-2.  This may show that a sufficient 
amount of BMP-2 must be present for enhancement to occur.  As mentioned above, the use 
of reduced amounts of relaxin may result in an enhancement effect at a lower BMP-2 
amount.   
The present study uses an amount of BMP-2 that is lower than the amount used in 
other studies with similar biomaterials [39].  This amount is also far below the safe clinical 
amount [7].  The overall goal of this study was to lower the previously published dose of 
BMP-2 with the addition of relaxin.  Figure 3.10 shows these comparisons.  With the 
addition of relaxin the amount of BMP-2 can be easily reduced by 50%.  A 75% reduction 
can also be seen when using 0.05µg of relaxin.  Figure 3.7 shows high magnification 
images of select groups.  These high magnification images demonstrate that there is no 
histological difference between a defect loaded with 1µg of BMP-2 and a defect loaded 




can lower BMP-2 doses.  This reduction supports the hypothesis that relaxin has the ability 
to lower BMP-2 doses with its enhancement effect, especially seen in the combination of 





Hollow hydroxyapatite microspheres can be used as a carrier for multiple proteins.  
In vitro release of BMP-2 and relaxin shows a slow and continuous release over the 
measured two-week span.  No inhibition to release was observed when both proteins were 
loaded in combination.  In the case of relaxin, more release was found in the combined 
group.  When BMP-2 and relaxin are combined in animal studies, an enhancement effect 
occurs with 0.5µg of BMP-2 and 0.05µg of relaxin.  When compared to a previously 
published dose (1µg per defect), a 50% reduction in BMP-2 amount when in combination 
with relaxin can achieve the same bone regeneration outcome.  A 75% reduction in BMP-
2 amount can produce comparable bone regeneration when combined with 0.05µg of 
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